Verrica Pharmaceuticals’ (VRCA) “Neutral” Rating Reiterated at HC Wainwright

Verrica Pharmaceuticals (NASDAQ:VRCA)‘s stock had its “neutral” rating reissued by investment analysts at HC Wainwright in a research report issued to clients and investors on Tuesday,Benzinga reports.

Separately, Needham & Company LLC reiterated a “hold” rating on shares of Verrica Pharmaceuticals in a research report on Wednesday, March 12th. Four analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $9.50.

Verrica Pharmaceuticals Trading Up 21.8 %

NASDAQ VRCA opened at $0.65 on Tuesday. Verrica Pharmaceuticals has a 1-year low of $0.38 and a 1-year high of $11.41. The company has a 50 day moving average of $0.62 and a 200-day moving average of $0.90. The firm has a market cap of $59.23 million, a price-to-earnings ratio of -0.35 and a beta of 1.68.

Verrica Pharmaceuticals (NASDAQ:VRCA) last released its quarterly earnings results on Tuesday, March 11th. The company reported ($0.24) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.01. Verrica Pharmaceuticals had a negative return on equity of 591.84% and a negative net margin of 625.06%. The firm had revenue of $0.34 million during the quarter, compared to analysts’ expectations of $1.30 million. On average, analysts forecast that Verrica Pharmaceuticals will post -1.46 earnings per share for the current year.

Hedge Funds Weigh In On Verrica Pharmaceuticals

Several large investors have recently made changes to their positions in VRCA. Caligan Partners LP acquired a new stake in Verrica Pharmaceuticals in the fourth quarter worth about $5,201,000. Boothbay Fund Management LLC bought a new position in shares of Verrica Pharmaceuticals in the 4th quarter valued at about $1,811,000. State Street Corp raised its stake in shares of Verrica Pharmaceuticals by 13.5% during the third quarter. State Street Corp now owns 512,821 shares of the company’s stock worth $744,000 after buying an additional 61,041 shares during the last quarter. Geode Capital Management LLC raised its stake in shares of Verrica Pharmaceuticals by 4.8% during the fourth quarter. Geode Capital Management LLC now owns 477,269 shares of the company’s stock worth $334,000 after buying an additional 21,789 shares during the last quarter. Finally, Sovran Advisors LLC acquired a new position in Verrica Pharmaceuticals in the fourth quarter valued at approximately $267,000. Institutional investors and hedge funds own 42.45% of the company’s stock.

Verrica Pharmaceuticals Company Profile

Verrica Pharmaceuticals Inc, a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts.